Faber Logo Skip to main content

Recent Transactions

Our latest work in the life sciences and high-tech fields.

Our work

TMS Co., Ltd. + JiXing Pharmaceuticals + RTW Investments, LP

Strategic Collaboration Agreements

The firm counseled TMS Co. Ltd. as it entered strategic collaboration agreements with JIXING Pharmaceuticals, subsequent to the assignment of TMS-007 global rights from Biogen to JIXING. TMS regained Japan rights to this compound, received a payment of JIXING equity, and obtained Japan rights to JX09. TMS contemporaneously received a private equity investment from RTW

Press Release
Claris Biotherapeutics, Inc. Logo

Claris Biotherapeutics, Inc.

Series A-3 Preferred Stock Financing

Claris Bio closes latest venture round to bring total financing to roughly $60 million, accelerating its late-stage clinical development of a novel therapeutic agent for neurotrophic keratopathy. Investors include Novo Holdings A/S, RA Capital, Mass General Brigham Ventures, and Janus Henderson Investors

Press Release
GV (Google Ventures) Logo

GV (Google Ventures)

Chroma Medicine Series B Financing

Representation of GV, as lead, ARCH Venture Partners and DCVC in Chroma Medicine’s $135M Series B Financing

Press Release
NextPoint Therapeutics, Inc. Logo

NextPoint Therapeutics, Inc.

Series B Financing - $80 million

NextPoint Therapeutics raises $80 million in Series B financing co-led by Leaps by Bayer, the impact investment arm of Bayer AG, and Sanofi Ventures, the strategic venture capital arm for Sanofi.  Additional new investors in the round include Invus, Catalio Capital Management, Sixty Degree Capital and PagodaTree Partners. Existing investors that took part in the financing include MPM Capital Management and Dana-Farber Cancer Institute

Paragon Therapeutics, Inc. Logo

Paragon Therapeutics, Inc. + Apogee Therapeutics, Inc.

Antibody Discovery and Option Agreement

Option for exclusive development and commercial rights to a suite of Paragon’s top-tier antibodies specifically engineered to target some of the largest and highest unmet needs in inflammatory and immunological conditions

Press Release
6 Dimensions Capital Logo

6 Dimensions Capital

VC Investments

Equity investments in multiple portfolio companies, including Hibercell

Puma Biotechnology, Inc. Logo

Puma Biotechnology, Inc.

Clinical Trial

CRO and Site Agreements for an Open-Label, Phase 2 Study with 30 Sites in 9 Countries exploring the efficiency of Neratinib on Patients with Solid Tumors with Somatic Human Epidermal Growth Factor Receptor (EGFR, HER2, HER3) Mutations Or EGFR Gene Amplification

See Study
Epalex Corporation Logo

Epalex Corporation

Series A-3 Financing

Series A-3 preferred equity financing to continue advancing Epalex’s two clinical-stage development programs

Praeventix, Inc. Logo

Praeventix, Inc.

Private Investment

Private Investment from Tellus BioVentures

Vertex Pharmaceuticals Incorporated Logo

Vertex Pharmaceuticals Incorporated

Acquisition of Private Company

Co-counsel to Vertex on acquisition of ViaCyte, a privately-held biotechnology company that received substantial research funding from the California Institute of Regenerative Medicine

Press Release
Versant Ventures Management, LLC Logo

Versant Ventures Management, LLC

Antibody Discovery and Collaboration Agreement

Multi-year collaboration with AbCellera to discover therapeutic antibodies for multiple targets selected by Versant’s portfolio of biologics-focused biotechnology companies

Press Release
Vizgen, Inc. Logo

Vizgen, Inc.

Series C Financing

Vizgen raises Series C equity funding led by Blue Water Life Science Advisors, LLC, ARCH Venture Fund X, L.P. and other existing investors

Press Release
Vernal Biosciences, Inc. Logo

Vernal Biosciences, Inc.

Series A Financing

Vernal Biosciences raises $21M Series A equity funding led by Dynamk Life Sciences Fund, L.P., Charles River Laboratories, Inc. and Ampersand 2020 Limited Partnership

Press Release
Artax Biopharma, Inc. Logo

Artax Biopharma, Inc. + Advent Life Sciences Fund II LP

Series B Financing (Series B4)

Artax Biopharma raises Series B-4 round of equity funding led by Advent Life Sciences Fund II LP, Advent Life Sciences LLP, Columbus Life Science Fund II, FCR, Hiyuli Ventures Limited, Belinda A. Termeer, and other existing investors, plus new investors including Sound Bioventures Fund I AB and and Eli Lilly

Press Release
Dianthus Therapeutics OpCo, Inc. Logo

Dianthus Therapeutics OpCo, Inc.

Series A Financing

Dianthus raises $100 million Series A financing led by 5AM Ventures, Fidelity Management & Research Company, Avidity Partners, Venrock, Fairmount Funds, Tellus BioVentures and other investors

Press Release
Summation Bio, Inc. Logo

Summation Bio, Inc.

Series A Financing

Summation Bio raises Series A equity funding led by RA Capital Healthcare Fund, L.P., RA Capital NEXUS Fund, L.P., RA Capital NEXUS Fund III, L.P., Blackwell Partners LLC and other existing investors

page 1 / 5

Here’s how we can help you

This site uses cookies. Some provide anonymous analysis of how our website is used and some are essential to make the website work. Other cookies enable personalized services or social media features to be used. By using our website, you agree to the use of cookies. To find out more, please see our Privacy Policy. You can disable cookies at any time by changing your browser settings.